Revenue EXPLOSION Coming?, page-43

Clinuvel is making a LOT of money right now from one single rare indication (EPP) and that is with US sales only just beginning. This "golden goose" you describe is not going to face competition from generics this decade imo. If you understood the company you would realise this "golden goose" is actually just the proof-of-concept disease that shows the amazing safety of the clinuvel drug and at the same time gathers data and gives authorities confidence in the company and what other diseases they can potentially treat. This is where you are going to see the real BIG FARM OF GOLDEN GEESE when Clinuvel get approval for their existing drug to treat Vitiligo, XP, VP, OTRs (organ transplant recipients), skin cancer sufferers, Stroke victims (85% of 15 Million currently untreated) and with their OTC products for people who want solar protection and DNA repair - so pretty much everyone! This mostly will come not from new drugs but from an existing FDA, EMA, TGA and Israel approved drug that is very safe and is now seeking new and currently untreated indications. This is a much simpler process than getting a new drug approved because safety is already proven - and if CUV gets approval for just one of the other indications it will make this a $100+ stock overnight.

Your comments about Epitan and previous management from over 15 years ago show you need to update your knowledge of Clinuvel. Clinuvel has now achieved FDA, EMA, TGA and Israel market approval for their drug and very, very few Australian biotechs can boast anything like this achievement. CUV has been profitable for many years now and are growing profits quickly with the recent commencement of sales into the US and they carry no debts. Furthermore CUV is also very undervalued compared to comparison stocks like MSB, TLX and PNV who have similar or higher valuations despite not being profitable and just burning cash and they do not have the approvals that CUV has. So the good news is it is not too late for you to buy some CUV while they are still at a bargain basement valuation.

All IMO, DYOR